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Parkinson’s disease (PD) is the second most common neurodegenerative disease. In
recent years, it has been shown that leucine-rich repeat kinase 2 (LRRK2) has a crucial
function in both familial and sporadic forms of PD. LRRK2 pathogenic mutations are
thought to result in an increase in LRRK2 kinase activity. Thus, inhibiting LRRK2 kinase
activity has become a main therapeutic target. Many compounds capable of inhibiting
LRRK2 kinase activity with high selectivity and brain availability have been described.
However, the safety of long-term use of these ATP-competitive LRRK2 kinase inhibitors
has been challenged by several studies. Therefore, alternative ways of targeting LRRK2
activity will have a great benefit. In this review, we discuss the recent progress in the
development of allosteric inhibitors of LRRK2, mainly via interfering with GTPase activity,
and propose potential new intra and interprotein interactions targets that can lead to
open doors toward new therapeutics.
Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease [1]. Despite the fact
that the etiology of PD is mostly unknown, genome-wide association studies have identified many
genetic mutations associated with increased risk of PD. Among all identified risk-genes, missense
mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) stand as the most common
single genetic cause of PD. LRRK2 is an atypical large protein, consisted of four protein–protein inter-
action (PPI) domains, as well as two domains conferring distinct enzymatic activities, GTPase
mediated by the Roc (Ras of complex proteins) domain and a serine–threonine kinase (Figure 1).
From numerous studies, it is clear that pathogenic mutations of LRRK2 result in a gain-of-function
and increased kinase activity [2–4]. Moreover, wild type LRRK2 kinase activity was shown to be
increased in patients with idiopathic PD [5], and both LRRK2-related PD and sporadic PD are clinic-
ally similar. As a result, considerable efforts were made toward the development of pharmacological
inhibitors of LRRK2 kinase activity as a therapeutic intervention. Many compounds capable of inhibit-
ing LRRK2 kinase activity have been described [6,7], and until now, there have been four generations
of advancement [8]. The most recently developed (third-generation) ATP-competitive LRRK2 kinase
inhibitors, including MLi-2 and PF-06685360, have an optimized potency, selectivity and brain avail-
ability [9,10]. Although the first kinase compounds are in clinical trials, several studies have reported
that inhibition of LRRK2 with several of these ATP-competitive inhibitors can cause kidney abnormal-
ities in rodents and an accumulation of lamellar bodies in type II pneumocytes in the non-human
primate lung [11–13]. While these histological alterations were reversible after drug withdrawal and
had no functional consequences [14], it is not completely clear whether the long-term use of such
inhibitor will result in different sequels. Furthermore, on a cellular level, it has been shown that these
ATP-competitive kinase inhibitors induce cellular recruitment of LRRK2 to microtubules [15–18]
which in turn reduces the kinesin — and dynamin-mediated transport along microtubules [19]. It is,
therefore, not unlikely that the side effect associated with the use of ATP-competitive LRRK2 kinase
inhibitors is a result of this altered localization of LRRK2. Thus, developing other approaches that
fine-tune LRRK2 kinase activity might be of an additional benefit.
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LRRK2 activation mechanism
Although the exact molecular mechanism is not completely understood, recent data suggest that LRRK2 goes
through a complex activation cycle, including membrane-recruitment via binding of upstream effectors to the
N-terminus and conformational activation via intramolecular interactions and dimerization (Figure 1).
Previous studies showed that LRRK2 exists both in the cytoplasm and as associated with membranous orga-
nelles [20–22]. In the cytosol, GTP-bound LRRK2 is mainly monomeric and has a low-kinase activity; while it
is predominantly dimeric and active when localized at membranes [20]. The N-terminal segment of LRRK2
interacts with the ubiquitous regulatory protein 14-3-3 in a phosphorylation-dependent manner and thereby
stabilizes the cytosolic localization of LRRK2 [23,24]. GTP-bound Rab proteins, including Rab29 and Rab32,
bind also to the N-terminus of LRRK2, but thereby recruit GTP-bound LRRK2 to the membrane. At the mem-
brane LRRK2 goes through a multi-step hydrolysis cycle, resulting in a dimeric, GDP-bound conformation of
LRRK2 [20]. It is unclear during which step dimerization occurs, however, it is mediated via the Roc and COR
domains and is crucial for GTP hydrolysis and to achieve maximum kinase activity. In the active conformation,
LRRK2 phosphorylates its substrates, GTP-bound Rab proteins. This shows that the GTPase and kinase activ-
ities are clearly linked. However it remains to be determined what exactly is the active conformation of LRRK2
at the membrane. Importantly, all different levels of regulation are essential for proper LRRK2 functioning and
therefore are all potential targets to allosterically inhibit LRRK2 activity. In this review, we will highlight the
recent advances in developing allosteric LRRK2 inhibitors and discuss our perspective for potential inhibitors
for LRRK2 aside from the ATP-binding pocket (Figure 2).
Figure 1. LRRK2 oscillate between different conformation for full kinase activation.
LRRK2 is mainly present in a monomeric GTP-bound form in the cytosol. This state is less active and can form a stable cytoplasmic complex with
14-3-3 proteins. Binding of activated Rab proteins induces membrane localization of LRRK2. At the membrane, GTP is hydrolyzed and the protein
dimerizes. During the GTPase cycle, the LRRK2 kinase domain gets fully activated and phosphorylates its substrates. The low affinity of LRRK2 for
GDP facilitates fast GDP release, rebinding of GTP and, subsequently monomerization of LRRK2 and return to the cytosol. Conventional
pharmacological inhibition of LRRK2 induces microtubule recruitment and formation of filamentous LRRK2, dimeric units of LRRK2 extended via
WD40 :WD40 or LRR : LRR interaction.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-
ND).
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Targeting the LRRK2 kinase domain
In general, classical kinase inhibitors that directly target the ATP-binding pocket (Type I inhibitors) usually
have broad selectivity profiles and most have significant off-target effects, unlike allosteric inhibitors which are
generally more selective. Whereas the development of classical inhibitors has benefited greatly from the exist-
ence of the natural small-molecule substrate, ATP, there are virtually no natural small molecule starting points
from which allosteric kinase modulators can be built. This renders allosteric kinase inhibitors more challenging
to develop.
Nevertheless, more rational approaches for the development of allosteric inhibitors and efficient high-
throughput screening are being utilized more recently and there are already successful examples of allosteric
kinase inhibitors in the clinic. This allowed Schaffner et al. [25] to identify a physiological form of vitamin
B12, 50-deoxyadenosylcobalamin (AdoCbl), as the first kinase inhibitor for LRRK2 that is not ATP-competitive.
The addition of AdoCbl markedly increased the susceptibility of LRRK2 to proteolysis, whereas conventional
LRRK2 kinase inhibitors, protected LRRK2 from proteolytic digestion. This suggests a conformational change
in LRRK2 upon binding to AdoCbl that is different from ATP-competitive inhibitors. Keeping in mind the
structural similarity between ATP and AdoCbl, both can be considered as adenosine derivatives and it could be
possible that vitamin B12 binds the ATP pocket at such a high concentration needed for its kinase inhibitory
effect (15 mg/ml vs. 500 pg/ml, the physiological serum concentration). Therefore, it has to be seen how specific
AdoCbl is for LRRK2 compared with other kinases.
Another possibility for allosteric targeting of the LRRK2 kinase domain arises from the fact that reposition-
ing of the activation loop of all kinases in the tyrosine kinase-like family is a common conformational change
for which LRRK2 is no exception. The conserved DFG motif (DYG motif in LRRK2) in the activation loop
tends to create a flexible conformation as a result of the presence of a small glycine residue in the enzyme,
which in turn allows the kinase to switch easily between active (DYG-in) and inactive (DYG-out) forms. Using
a combination of structure-based analysis and site-directed mutagenesis accompanied by cell-based assays,
Schmidt et al. [26] characterized the mechanistic role of the DYG motif in regulating LRRK2 kinase activity.
Figure 2. Potential strategies for allosteric inhibition of LRRK2.
Peptidomimetics can be used to disrupt LRRK2 dimerization (RocCOR : RocCOR, WD40 :WD40, WD40 : CORB,) and to interfere with LRRK2 PPIs
(ARM domain: FADD). GTP-binding inhibition (FX2149) rescues LRRK2-mediated cellular toxicity. Peptide capping can prevent dephosphorylation of
constitutively phosphorylated residues needed for interaction with 14.3.3. Nanobodies can be used to target and stabilize a low-kinase active
conformation of LRRK2.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-
ND).
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Their data suggest that by stabilizing the DYG-out confirmation (type II inhibitors), it should be possible to
inhibit LRRK2 activity. Ray and Liu [27] identified four potential inhibitors of LRRK2 through docking of
known DFG-out inhibitors into a LRRK2 model [28]. The next step will be the development of more LRRK2
specific DFG-out inhibitors, which might be challenging especially for the G2019S mutation that lies within the
DYG motif and induces a conformational bias towards the active (DYG-in) conformation [28].
Targeting the G-protein cycle
Both the GTPase and the kinase function of LRRK2 are crucial and depend on each other. Furthermore,
LRRK2 GTPase activity might be crucial for LRRK2 pathogenicity. In fact, several of the tested pathogenic
RocCOR mutations were shown to either increase the affinity for GTP [15,29,30] and/or decrease the rate of
GTP hydrolysis [31–36], which is expected to result in enrichment of LRRK2 in the GTP-bound state [34]. In
support to this notion, the R1398H protective Roc domain variant is associated with an increased rate of GTP
hydrolysis and a weakened binding to GTP [37]. Through a combination of computer-aided drug design and
biofunctional screens, Li et al. [38] discovered two compounds that reduce GTP-binding and subsequently
inhibit LRRK2 kinase activity. The same group later designed an analog of their parent compound to increase
its brain penetrance and in vivo efficacy [39]. Furthermore, reducing GTP-binding activity with these com-
pounds attenuated the impairment of mitochondrial and lysosomal transport in cells expressing R1441C [40]
and increased polyubiquitylation of G2019S [41]. Their results highlight the potentiality of targeting LRRK2
kinase activity by targeting the Roc domain.
Using a bacterial homolog of LRRK2, we have shown that the isolated RocCOR domain is primarily dimeric
when bound to GDP or when no nucleotides are present, but monomeric when GTP bound [42]. Furthermore,
we have revealed that the COR domain is crucial for LRRK2 dimerization [43] and constructs with a truncated
COR protein are associated with an impaired dimerization and a significantly lowered (700 times) GTPase
activity. Expectedly, impairing dimerization also alters autophosphorylation levels, indicating that both enzym-
atic activities are dependent on dimerization [34,43–45]. Furthermore, LRRK2 dimerization was shown to be
stabilized by multiple domain–domain interactions. Greggio et al. [46] revealed an interaction between Roc and
LRR domains. Later, intramolecular interaction was detected between ROC : ROC [45] and ROC : COR [33].
Besides COR domain, the WD40 domain is also involved in LRRK2 dimerization and pathogenicity [47].
Recently, the crystal structure of the WD40 domain of human LRRK2 was reveled at 2.6-Å resolution and
showed a dimeric assembly, that was further confirmed by measurements in solution [48]. The deletion of the
WD40 repeats led to impaired dimer formation accompanied by diminished kinase activity and altered LRRK2
cellular localization [47]. Although it is not clear how mutations affect LRRK2 dimerization or PPIs, the crystal
structure of dimeric LRRK2 WD40 identified surface patches that provide a structure-based template for poten-
tial therapeutic interventions. Recently, an atomic model of microtubule-associated LRRK2 was built using
cryo-electron tomography [19,49], which further supported the vital need of ROC, COR, and WD40 for
LRRK2 dimerization. Thus, any biologic that impairs LRRK2 dimerization is expected to finetune LRRK2
kinase activity.
Interestingly, the most recent model of LRRK2 revealed by Deniston et al. [19] provides a unique feature of
LRRK2 represented in a 28-amino acid α-helix located terminally following the WD40 domain and extends
along the entire length of the kinase domain. Intriguingly, this α-helix showed extensive interactions with the
kinase domain. Furthermore, this helix is juxta-positioned to the COR-B domain. This might suggest a regula-
tory function of this C-terminal helix in which it acts as an anchoring element that connects COR-B, the
kinase, and the WD40 domain [19]. Thus, targeting this particular α-helix (as discussed below) can impair its
regulatory function and affect the stability of the kinase domain.
Another successful approach to specifically bind a certain conformation of a protein was achieved via the use
of Nanobodies [50,51]. Nanobodies are robust small (15 kDa) single-domain antigen-binding fragments
derived from heavy chain-only antibodies, naturally occurring in Camelids, which can be easily produced by a
wide range of different hosts. Unlike conventional antibodies, antigen-recognition sites of nanobodies typically
form a convex surface with a large elongated complementarity-determining region loop 3 (CDR3) capable of
reaching hidden pockets that are less antigenic for other types of binders [52]. This unique feature allowed for
a conformation-specific binding between nanobodies and their corresponding antigen [53,54]. Actually, it was
shown that nanobodies could be used to trap a kinase in a specific conformation and subsequently affect
kinase activity [50,55,56]. Furthermore, Leemans et al. [57] recently used a bacterial LRRK2 homolog and iden-
tified two conformation-specific nanobodies that trapped the protein in a GTP-bound state and subsequently
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-
ND).
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increased the GTP turnover rate and reverted the decrease in GTPase activity caused by a PD-analogous muta-
tion. In this regard, the generation of LRRK2 conformation-specific nanobodies has the potential to also trap
LRRK2 in both a kinase active or a kinase-inactive conformation. Besides being a valuable tool to understand
LRRK2 dynamics and domains plasticity, LRRK2/nanobody structures could form the basis for the future
rational design of LRRK2 allosteric inhibitors. Furthermore, nanobodies were shown to be distributed widely
and rapidly through the human body once administered [58]. The fusion of nanobodies to cell-penetrating pep-
tides generated nanobodies that are able to get access into cells (transbodies) [59–61], and different approaches
were successfully utilized to allow nanobodies to cross the blood-brain barrier (BBB) [62,63]. Nevertheless, the
use of nanobodies to target intracellular proteins is still challenged by the short half-life of the nanobodies in
the bloodstream and the relatively large amount of nanobodies needed to obtain the desired effect.
Targeting LRRK2 protein–protein interactions
Most kinases exert their biochemical activity as being a partner in a complex network of PPIs. Similarly,
LRRK2 was also shown to be functioning as a scaffolding protein [64,65], that pre-assembles signaling com-
plexes at specific cellular localizations [66]. In turn, targeting LRRK2 scaffolding interactions is another attract-
ive strategy to reverse its associated pathogenicity. In this regard, LRRK2 was shown to mediate neuronal cell
death through interaction as a scaffold to sequester the ASK1 signaling kinases (ASK1, MKK6, and p38
MAPK) [65]. Also, LRRK2 was shown to bind to synaptic vesicles via an interaction of the WD40 domain and
vesicle-associated proteins. Importantly, the toxicity induced by overexpression of full-length LRRK2 in
primary neuronal cultures was mimicked by ectopic expression of a construct containing only the C-terminal
WD40 domain of LRRK2 [67]. In a similar context, it was shown that LRRK2 neuronal cell death takes place
in a FADD-dependent manner [68] and prevention of the physical interaction between FADD and LRRK2 is
neuroprotective in primary neurons expressing mutant LRRK2 [69]. The group could also identify the region
of LRRK2 involved in the interaction and generated a docking model that uncovered a strong hydrophobic core
mediated via α-helices interactions between the LRRK2 ARM domain and FADD protein. This model can
provide the basis for a structure-based design of small molecule inhibitors with a potential therapeutic value.
As discussed earlier, LRRK2 kinase activation is regulated by 14-3-3 protein binding, and pathogenic muta-
tions of LRRK2 were reported to impair the protein ability to interact with 14-3-3 protein [70] which in turn is
associated with neurite shortening and cell death [71]. Taking into account that 14-3-3 is binding to LRRK2 in
a phosphorylation-dependent manner, it has been suggested to protect the phosphorylation residues from
being dephosphorylated when unbound to 14-3-3, with a peptide ‘cap’ [72]. Recently, the exact 14-3-3 binding
sites in LRRK2 were identified [73,74]. Since both natural and synthetic molecules are already available in the
literature that achieve their physiological activities by stabilizing 14-3-3 binding with their target protein
(reviewed in [75]), it sounds plausible to utilize available approaches [75,76] to generate a more specific
LRRK2-14-3-3 complex stabilizer.
While small molecules have had success as therapeutic kinase inhibitors, they generally failed to address the
flat and large nature of PPI surfaces. However, with the recent fast-tracked advance in drug discovery
approaches, new PPI-based drugs were delivered leading to an expansive possibility to target what was previ-
ously considered ‘undruggable’. Indeed, targeting Kinases PPI interfaces has been shown as a valid strategy to
allosterically inhibit kinases. Different approaches have been utilized and can be reflected in LRRK2 targeting.
A fluorescence polarization (FP) competitive binding assay can be developed to screen for compounds that
disrupt LRRK2 dimerization similar to the approach of Rettenmaier et al. [77] which allowed for the identifica-
tion of potent disruptors of the interaction between PDK1 and PIFtide. It is convincible to utilize this tech-
nique to screen for RocCOR : RocCOR or WD40 :WD40 interactions, provided that both domains are well
expressed and stably produced. In this regard, the dimerization interface can be mimicked by fluorescently
labeled peptides as FP probes for a competitive binding assay that should be suitable for a high-throughput
screen.
Furthermore, a side-directed approach, disulfide trapping (or tethering), was developed previously to allow
for a more straightforward characterization and interrogation of allosteric sites on protein kinases with small
molecules. Disulfide trapping involves screening disulfide-containing compounds for their ability to form a
mixed disulfide with a natural or engineered cysteine residue near a site of interest on a protein target [78,79].
This technique allowed for the identification of potent inhibitors of many disease-related tyrosine kinases
[80,81]. This approach can be of great help to discover inhibitors for the WD40 : FADD interaction, or to
disrupt C-helix mediated kinase stability; provided that residues involved in each interaction are well identified.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-
ND).
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Another potentiality arises from the fact that α-helices are one of the most abundant secondary structural
elements involved in PPI interfaces, which confers the ability to bind large and relatively flat surfaces both effi-
ciently and specifically. Accordingly, the use of a peptide to mimic such an α-helix can lead to specific disrup-
tion of PPIs. Interestingly, although peptidomimetics are small compared with their parent protein, they have
similar specificity toward their targets as biologics. Moreover, peptides are more compelling binders to PPIs
interfaces, and exert less toxicity when compared with small molecule drugs, which often produce toxic meta-
bolites. In contrast with small molecules, peptides are degraded into amino acids, which are in turn not toxic
or harmful for cells. Different approaches have shown success in producing biologics that therapeutically
inhibit PPIs as peptidomimetics. Furthermore, to overcome the rapid degradation with proteases and to stabil-
ize the helical foldability, non-natural amino acids can be used as building blocks of peptides, which in turn
create an opportunity to produce diverse scaffolds with modified chemical and functional properties. A step
further toward better bioactive peptides was achieved by engineering a non-native carbon–carbon bond con-
straint with olefin tethers into the peptide sequence [82]. This new hydrocarbon-stapled backbone approach
has provided a platform for many successful α-helical peptidomimetics [83–85].
Utilizing any of these approaches in combination with crystal structures or protein models of LRRK2 (or
certain domains of interest) is expected to lead to new biologics that can alter LRRK2 kinase and cellular
pathogenicity in a completely new mechanism different from conventional kinase inhibitors.
Conclusions
Although potent ATP-competitive kinase inhibitors are available for LRRK2, they induce alteration in LRRK2
conformations and are associated with the recruitment of LRRK2 to microtubules, which in turn results in
impaired vesicular transportation within the cell. Allosteric inhibition of LRRK2 is expected to provide an alter-
native way, potentially without objectionable alteration of cellular localization of the protein. Furthermore, sta-
bilization of different conformation of LRRK2 would be of great importance from a structural point of view. So
far, GTP-binding has been successfully targeted and at least two compounds are available with the ability to
prevent LRRK2-associated neuronal damage. Although a crystal structure of LRRK2 is still not available yet,
recent data revealed a high-resolution structure of LRRK2-bound to microtubules [19,49]. Such advancement
should allow for structure-based targeting and design of novel allosteric inhibitors. Furthermore, selective nano-
bodies have already been identified against conformation-specific forms of a bacterial homolog of LRRK2.
Thus, identification of conformation-specific nanobodies against LRRK2 would provide a crucial tool for
further characterization of LRRK2 activation steps and biochemical kinetics. The use of peptide-mimetics has
been substantially increasing as a successful way of targeting PPIs. In particular, stapled peptides mimicking
α-helical structure showed potency to stand as an efficient therapeutic molecule. Accordingly, utilizing such an
approach for targeting LRRK2 dimerization interface and/or LRRK2 PPIs is expected to render new useful
molecules that can finetune LRRK2 kinase activity. It is worth mentioning that LRRK2 is not only targeted on
a protein level, and targeting LRRK2 mRNA with antisense oligonucleotides has shown to be effective in rescu-
ing LRRK2-dependent cellular dysfunction, with a potentiality to correct PD-toxicity [86].
In summary, we have discussed the most promising approaches for allosteric targeting of LRRK2 according
to the current knowledge of LRRK2 and its pathogenicity. Besides its potential therapeutic use, such inhibitors
would help understanding more about the unique activation mechanism of LRRK2 and its cellular interactions.
Perspectives
• Allosteric inhibition of LRRK2 is expected to provide an alternative way potentially without
objectionable alteration of cellular localization of the protein. Furthermore, stabilization of dif-
ferent conformation of LRRK2 would be of great importance from a structural point of view.
• Although potent ATP-competitive kinase inhibitors are available for LRRK2, they induce alter-
ation in LRRK2 conformations and are associated with the recruitment of LRRK2 to microtu-
bules, which in turn results in impaired vesicular transportation within the cell. So far,
GTP-binding has been successfully targeted and at least two compounds are available with
the ability to prevent LRRK2-associated neuronal damage.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-
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• Although a crystal structure of LRRK2 is still not available yet, recent data revealed a 14-A°
structure of LRRK2-bound to microtubules. Such advancement should allow for structure-
based targeting and design of novel allosteric inhibitors. Furthermore, selective nanobodies
have already been identified against conformation-specific forms of a bacterial homolog of
LRRK2. Thus, identification of conformation-specific nanobodies against LRRK2 would
provide a crucial tool for further characterization of LRRK2 activation steps and biochemical
kinetics.
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